Skip to content

KW-6356

Also called adenosine A2A antagonist / inverse agonist

Selective adenosine A2A receptor antagonist AND inverse agonist.

  • TypeBioregulator
  • FormOral
  • Researched forCognitive & Mood

Where to get KW-6356

Disguised Alpha
Oral
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop oral at Disguised Alpha

The short version

  • Why people research itFocus, memory, neuroprotection, mood and stress resilience.
  • What the evidence isKyowa Kirin discontinued the program despite the positive phase 2b readout.
  • What to watchNew hallucinations or confusion.

How KW-6356 works

KW-6356 treats Parkinson's disease without touching a dopamine receptor, and the way it does that is one of the more elegant pieces of pharmacology in this Vault.

Where the receptor is, which is the whole trick. Adenosine A2A receptors are concentrated, almost exclusively in the brain, on the striatopallidal medium spiny neurons of the indirect basal ganglia pathway — the same population that carries dopamine D2 receptors. The two receptors sit together and form heteromers.

A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts that brake without stimulating dopamine receptors directly, which is why it does not carry the dyskinesia profile of dopaminergic drugs. The inverse-agonist part means it also suppresses A2A signaling that happens with no adenosine bound — a step beyond istradefylline, the approved A2A antagonist it is usually compared to.

  • Oral

On the goal map: Catecholamine & dopaminergic drive (Focus, memory & cognition)

Research on KW-63565 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • Phase 2b, 503 patients, 24 weeks. So more was not better.

  • Kyowa Kirin discontinued the program despite the positive phase 2b readout. That is a commercial decision rather than a safety finding.

Correlative data

  • The approved comparator, istradefylline, is a plain A2A antagonist and is licensed for OFF-episodes in Parkinson's. That drug's record is the closest thing to a read on what this class does over time.

How the mechanism reads

  • Adenosine A2A antagonist AND inverse agonist. A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts the brake without stimulating dopamine receptors directly.

    Mechanistic
  • The inverse-agonist part also suppresses A2A signaling occurring with no adenosine bound — a step beyond a plain antagonist. Caffeine is a non-selective adenosine antagonist, which is why the subjective alertness people chase here is a far cruder version of the same lever.

    Mechanistic

Sources

  • Maeda T, et al. Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease. Parkinsonism and Related Disorders 2023 · PMID 37948832
  • Tayama T, et al. Population Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW-6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease. Clinical Pharmacology in Drug Development 2024 · PMID 38178727
  • Ohno Y, et al. In vitro pharmacological profile of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist. Molecular Pharmacology 2023 · PMID 36894319
  • Ohno Y, et al. Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets. European Journal of Pharmacology 2023 · PMID 37146707
  • Ohno Y, et al. The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets. Journal of Pharmacological Sciences 2023 · PMID 37257947

KW-6356 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Hallucinations or psychosis, since dopamine-pathway disinhibition can worsen them.
  • Marked dyskinesia, as adenosine A2A blockade lifts the brake on striatal neurons.
  • Liver disease, given read-across to the related istradefylline.
  • Taking strong CYP3A4 inhibitors or inducers.
  • Pregnancy, with no reproductive toxicity data in people.

What’s expected

  • Less motor OFF time in Parkinson's trials.
  • Dyskinesia or nausea in some participants.
  • A single 106-person randomized trial is the whole human safety database.

Watch for

  • New hallucinations or confusion.
  • Involuntary writhing movements.
  • Dark urine, itching or pale stool from the liver.

Labs that tell you it’s working

  • Comprehensive Metabolic Panel: liver enzymes, as A2A antagonist class members show ALT rises.
  • Cystatin C with eGFR: renal handling of a new chemical entity.

Selective adenosine A2A antagonist and inverse agonist that lifts the brake on striatal D2 neurons without direct dopamine stimulation. PMID 37948832 PMID 38178727

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

KW-6356 FAQ4 common questions

Is KW-6356 approved for human use?
No. KW-6356 is a research compound.
What is KW-6356 researched for?
Focus, memory, neuroprotection, mood and stress resilience.
Which labs show whether it's doing anything?
Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for KW-6356: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what KW-6356 is. Skool covers how it is run.

Free on this page

What KW-6356 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What KW-6356 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool